Dr Mark Lythgoe
LightNews LightNews
drmarklythgoe.bsky.social
Dr Mark Lythgoe
@drmarklythgoe.bsky.social
490 followers 66 following 4 posts

Medical Oncology fellow & Pharmacist at @imperialcollege @ImperialSandC doing PhD in #cancer #microbiome -interest in health policy, drug development & @rovers

Videos
Economics 59%
Biology 24%
Posts Replies Media Videos

Reposted by Mark P. Lythgoe

yukselurun.bsky.social
Yüksel Ürün @yukselurun.bsky.social · Dec 30
Early-onset cancers (<50 yrs) are rising globally, linked to early-life exposures like diet, lifestyle, & microbiome changes. Awareness & dedicated studies are crucial. #Cancer #EarlyOnsetCancer #Oncology @oncoalert.bsky.social
rdcu.be/d49Ol

drmarklythgoe.bsky.social
Dr Mark Lythgoe @drmarklythgoe.bsky.social · Dec 29
Our thoughts on the evolving #posology of #Immunecheckpointinhibitors in
@trends in #Cancer

www.cell.com/trends/cance...
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations
Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits and challenges of this administration route, including potential implications for patient care.
www.cell.com

drmarklythgoe.bsky.social
Dr Mark Lythgoe @drmarklythgoe.bsky.social · Dec 29
#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.

Will this be the preferred route of administration or will this suppress the development of new biosimilars?

@oncodaily.bsky.social @hemoncwarner.bsky.social

drmarklythgoe.bsky.social
Dr Mark Lythgoe @drmarklythgoe.bsky.social · Dec 4
Wow #bluesky added to #altrimetric scores!

Reposted by Franz Essl, John Newman, Lisa M. Given , and 12 more

bsky.app
Bluesky @bsky.app · Dec 3
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
altmetric.com Altmetric @altmetric.com · Dec 3
There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research.

A Place of Joy.
‘A place of joy’: why scientists are joining the rush to Bluesky Researchers say the social-media platform — an alternative to X — offers more control over the content they see and the people they engage with.: https://www.nature.com/articles/d41586-024-03784-6

Reposted by Arash Rashidian, Franz Essl, James P. Collins , and 18 more

altmetric.com
Altmetric @altmetric.com · Dec 3
There are already many articles for which there is more attention on Bluesky than on other comparable micro-blogging sites, meaning the academic community and the general public have clearly adopted Bluesky as one of its core places to disseminate and discuss new research.

A Place of Joy.
‘A place of joy’: why scientists are joining the rush to Bluesky Researchers say the social-media platform — an alternative to X — offers more control over the content they see and the people they engage with.: https://www.nature.com/articles/d41586-024-03784-6

drmarklythgoe.bsky.social
Dr Mark Lythgoe @drmarklythgoe.bsky.social · Nov 27
Hugely interesting paper in
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?

www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com

Reposted by Mark P. Lythgoe

n8pennell.bsky.social
Nathan Pennell MD, PhD, FASCO @n8pennell.bsky.social · Nov 18
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice
Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the ...
ascopubs.org

Reposted by Mark P. Lythgoe

bmj.com
The BMJ @bmj.com · Nov 15
The World Health Organization notes 300 essential drugs are now in shortage.

What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...